Morgan Stanley analyst Matthew Harrison maintained a Buy rating on Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) today and set a price target of $47. The company’s shares opened today at $36.05.
According to TipRanks.com, Harrison is a 4-star analyst with an average return of 11.9% and a 60.3% success rate. Harrison covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Global Blood Therapeutics, and Voyager Therapeutics Inc.
Biohaven Pharmaceutical Holding Co Ltd has an analyst consensus of Strong Buy, with a price target consensus of $52, a 44.2% upside from current levels. In a report issued on October 1, Cantor Fitzgerald also maintained a Buy rating on the stock with a $57 price target.
Based on Biohaven Pharmaceutical Holding Co Ltd’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $39.27 million. In comparison, last year the company had a GAAP net loss of $42.92 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders.